메틸말론산혈증(MMA) 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 5.8%로 성장할 전망이며, 125억 달러로 성장이 예측됩니다. 예측 기간에 전망되는 성장은 신생아 스크리닝 프로그램 확대, 헬스케어 전문가 의식 향상, 유전자 치료 진보, 희귀 질환 연구에 대한 투자 증가, 전문적 치료의 가용성 향상 등의 요인에 의해 초래됩니다. 이 기간에 예상되는 주요 동향으로는 유전자 편집 기술 진보, 조기 발견을 위한 진단 기술 강화, 효소 보충 요법 진보, 정밀 의료 접근법 채택, 신생아 유전자 스크리닝 프로그램 실시 확대 등이 있습니다.
대사성 질환과 비타민 결핍증의 유병률 증가는 메틸말론산혈증(MMA) 시장의 성장을 가속할 것으로 예측됩니다. 대사장애는 신체가 특정 영양소를 처리하거나 에너지를 생산하거나 세포 내 화학반응을 조절하는 데 어려움을 겪는 상태입니다. 비타민 결핍증은 신체가 제대로 기능하기에 충분한 특정 비타민이 부족해 생깁니다. 대사 이상이나 비타민 결핍증의 증가는 식생활의 혼란, 앉기 쉬운 생활, 스트레스 레벨의 고조가 주된 원인이 되고 있습니다. 가공식품, 설탕, 건강하지 않은 지방이 많고 필수 영양소가 부족하기 쉬운 현대의 식생활은 비타민과 미네랄의 결핍을 조장하고 있습니다. 이러한 대사 이상이나 비타민 부족, 특히 비타민 B12의 결핍은, 메틸말로닐-CoA의 대사를 저해해, 메틸말론산의 축적이나 MMA의 악화로 이어집니다. 예를 들어 2024년 11월 미국 국립보건연구소는 비타민B12 결핍증 유병률이 4.6%에서 5.2%로 상승했고, 2023년 3분기부터 4분기 사이 507개 사례가 추가됐다고 보고했습니다. 그 결과 대사성 질환이나 비타민 결핍증 발생률 증가가 MMA 시장 확대에 박차를 가하고 있습니다.
MMA 시장의 주요 기업은 MMA의 유전적 원인을 표적으로 하고, 이를 앓고 있는 환자의 독성 대사산물의 축적을 억제하기 위해 효소 기능을 강화함으로써 치료 성과를 개선하기 위해 mRNA 기반 치료법 등의 혁신적인 솔루션의 개발에 주력하고 있습니다. mRNA 기반 치료법은 메신저 RNA를 사용하여 유전성 질환을 포함한 질병의 치료에 도움이 되는 특정 단백질을 생산하도록 세포에 지시합니다. 예를 들어 2024년 6월 미국 제약 및 바이오 기술 기업 모더나는 FDA로부터 mRNA-3705를 START 시험 프로그램에 포함하는 승인을 획득했습니다. 이 치료제는 프로피온산혈증에 대한 mRNA-3927 프로그램에서도 채택되고 있는 Moderna 독자적인 지질 나노입자(LNP) 시스템을 사용하고 있습니다. FDA는 mRNA-3705에 희귀병용의약품, 패스트트랙, 희귀소아질환 지정을 부여하여 개발과 임상의 진척을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 메틸말론산혈증(MMA) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 메틸말론산혈증(MMA) 시장 : 성장률 분석
- 세계의 메틸말론산혈증(MMA) 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 메틸말론산혈증(MMA) 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 메틸말론산혈증(MMA) 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 메틸말론산혈증(MMA) 시장 : 적응증별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 아시도시스
- 케토시스
- 고암모니아혈증
- 저혈당
- 고혈당
- 호중구감소증
- 기타 적응증
- 세계의 메틸말론산혈증(MMA) 시장 : 장애 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 호모시스틴뇨증
- 단리 메틸말론산뇨증
- 메틸말론산뇨증의 복합
- 세계의 메틸말론산혈증(MMA) 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 약국
- 클리닉
- 기타 유통 채널
- 세계의 메틸말론산혈증(MMA) 시장 : 아시도시스 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 대사성 아시도시스
- 젖산 아시도시스
- 세계의 메틸말론산혈증(MMA) 시장 : 케토시스 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 굶주림 유발성 케토시스
- 당뇨병성 케토아시도시스
- 세계의 메틸말론산혈증(MMA) 시장 : 고암모니아혈증 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 급성 고암모니아혈증
- 만성 고암모니아혈증
- 세계의 메틸말론산혈증(MMA) 시장 : 저혈당 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 공복시 저혈당
- 반응성 저혈당
- 세계의 메틸말론산혈증(MMA) 시장 : 호중구 감소증 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 심한 호중구 감소증
- 주기성 호중구 감소증
- 세계의 메틸말론산혈증(MMA) 시장 : 기타 적응증 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 발육 부전
- 발달 지연
- 신경증상
- 신장 기능 장애
제7장 지역별 및 국가별 분석
- 세계의 메틸말론산혈증(MMA) 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 메틸말론산혈증(MMA) 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 메틸말론산혈증(MMA) 시장 : 경쟁 구도
- 메틸말론산혈증(MMA) 시장 : 기업 프로파일
- Moderna Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Lonza Group Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Alexion Pharmaceuticals Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- PTC Therapeutics Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Ironwood Pharmaceuticals Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Wockhardt Limited
- Spectrum Chemical Manufacturing Corp.
- Asklepios BioPharmaceutical Inc.(AskBio)
- Selecta Biosciences Inc.
- BTG International Inc.
- BridgeBio Pharma Inc.
- VectivBio Holding AG
- Supriya Lifescience Ltd.
- Recordati Rare Diseases Inc.
- Agios Pharmaceuticals Inc.
- AdvaCare Pharma USA LLC
- LogicBio Therapeutics Inc.
- HemoShear Therapeutics LLC
- Manus Aktteva Biopharma LLP
- Deccan Nutraceuticals Pvt. Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 메틸말론산혈증(MMA) 시장(2029년) : 새로운 기회를 제공하는 국가
- 메틸말론산혈증(MMA) 시장(2029년) : 새로운 기회를 제공하는 부문
- 메틸말론산혈증(MMA) 시장(2029년) : 성장 전략
제36장 부록
AJY
Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder in which the body is unable to effectively break down certain proteins and fats due to a deficiency in the enzyme methylmalonyl-CoA mutase or a related coenzyme, vitamin B12. The severity of MMA symptoms can vary, but they often include vomiting, lethargy, poor feeding, developmental delay, seizures, and failure to thrive.
The primary indications for methylmalonic acidemia (MMA) include acidosis, ketosis, hyperammonemia, hypoglycemia, hyperglycemia, neutropenia, and other related conditions. Acidosis refers to an excess of acid in the blood, resulting in a lower-than-normal pH level. There are various types of disorders associated with MMA, such as homocystinuria, isolated methylmalonic acidurias, and combined methylmalonic aciduria. These treatments and interventions are available through different distribution channels, including hospitals, pharmacies, clinics, and other outlets.
The methylmalonic acidemia (MMA) market research report is one of a series of new reports from The Business Research Company that provides methylmalonic acidemia (MMA) market statistics, including the methylmalonic acidemia (MMA) industry global market size, regional shares, competitors with the methylmalonic acidemia (MMA) market share, detailed methylmalonic acidemia (MMA) market segments, market trends, and opportunities, and any further data you may need to thrive in the methylmalonic acidemia (MMA) industry. This methylmalonic acidemia (MMA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The methylmalonic acidemia (MMA) market size has grown strongly in recent years. It will grow from $9.39 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to factors such as the rising incidence of metabolic disorders and vitamin deficiencies, increased healthcare spending, greater health consciousness, a higher prevalence of genetic disorders, and growing demand from various end-user industries.
The methylmalonic acidemia (MMA) market size is expected to see strong growth in the next few years. It will grow to $12.50 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth projected for the forecast period is driven by factors such as the expansion of newborn screening programs, increased awareness among healthcare professionals, advancements in gene therapy, growing investments in rare disease research, and improved availability of specialized treatments. Key trends expected during this period include advancements in gene editing technologies, enhanced diagnostic techniques for early detection, progress in enzyme replacement therapies, the adoption of precision medicine approaches, and the growing implementation of newborn genetic screening programs.
The rising prevalence of metabolic disorders and vitamin deficiencies is expected to drive the growth of the methylmalonic acidemia (MMA) market. Metabolic disorders are conditions where the body struggles to process certain nutrients, produce energy, or regulate chemical reactions within cells. Vitamin deficiencies occur when the body lacks enough specific vitamins to function properly. The increase in metabolic disorders and vitamin deficiencies is largely attributed to poor diets, sedentary lifestyles, and heightened stress levels. Modern diets, which are often rich in processed foods, sugars, and unhealthy fats while lacking essential nutrients, contribute to deficiencies in vitamins and minerals. These metabolic disorders and vitamin deficiencies, especially vitamin B12 deficiency, disrupt methylmalonyl-CoA metabolism, leading to the buildup of methylmalonic acid and worsening MMA. For example, in November 2024, the National Institutes of Health reported that the prevalence of vitamin B12 deficiency rose from 4.6% to 5.2%, adding 507 cases between the third and fourth quarters of 2023. As a result, the growing incidence of metabolic disorders and vitamin deficiencies is fueling the expansion of the MMA market.
Leading companies in the MMA market are focusing on developing innovative solutions, such as mRNA-based therapies, to improve treatment outcomes by targeting the genetic causes of MMA and enhancing enzyme function to reduce the accumulation of toxic metabolites in affected individuals. mRNA-based therapies use messenger RNA to instruct cells to produce specific proteins that help treat diseases, including genetic disorders. For example, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received FDA approval to include mRNA-3705 in the START pilot program, a significant advancement for rare disease treatments. mRNA-3705 is an investigational therapy for MMA caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. The therapy uses Moderna's proprietary lipid nanoparticle (LNP) system, also employed in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drug, fast track, and rare pediatric disease designations, expediting its development and clinical progress.
In October 2022, Alexion Pharmaceuticals, a US-based biopharmaceutical company, acquired LogicBio Therapeutics for approximately $68.2 million. This acquisition aims to accelerate Alexion's growth in genomic medicines by utilizing unique technology, a talented rare disease research team, and expertise in preclinical development. LogicBio Therapeutics, Inc. is a US-based biotechnology company specializing in gene-editing and gene therapy solutions for rare genetic diseases, including MMA.
Major players in the methylmalonic acidemia (mma) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.
North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in methylmalonic acidemia (MMA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the methylmalonic acidemia (MMA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The methylmalonic acidemia (MMA) market consists of revenues earned by entities by providing services such as medical management, dietary support, and vitamin and medication therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The methylmalonic acidemia market includes sales of hydroxocobalamin, vitamin B12 tablets, other pharmaceutical and therapeutic products, dietary products, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Methylmalonic Acidemia (MMA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on methylmalonic acidemia (mma) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for methylmalonic acidemia (mma) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The methylmalonic acidemia (mma) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Indication: Acidosis; Ketosis; Hyperammonemia; Hypoglycaemia; Hyperglycaemia; Neutropenia; Other Indications
- 2) By Disorder Type: Homocystinuria; Isolated Methylmalonic Acidurias; Combined methylmalonic Aciduria
- 3) By Distribution Channel: Hospitals; Pharmacies; Clinics; Other Distribution Channels
- Subsegments:
- 1) By Acidosis: Metabolic Acidosis; Lactic Acidosis
- 2) By Ketosis: Starvation-Induced Ketosis; Diabetic Ketoacidosis
- 3) By Hyperammonemia: Acute Hyperammonemia; Chronic Hyperammonemia
- 4) By Hypoglycemia: Fasting Hypoglycemia; Reactive Hypoglycemi
- 5) By Hyperglycemia: Transient Hyperglycemia; Persistent Hyperglycemia
- 6) By Neutropenia: Severe Neutropenia; Cyclic Neutropenia
- 7) By Other Indications: Failure to Thrive; Developmental Delays; Neurological Symptoms; Renal Dysfunction
- Companies Mentioned: Moderna Inc.; Lonza Group Ltd.; Alexion Pharmaceuticals Inc.; PTC Therapeutics Inc.; Ironwood Pharmaceuticals Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Methylmalonic Acidemia (MMA) Market Characteristics
3. Methylmalonic Acidemia (MMA) Market Trends And Strategies
4. Methylmalonic Acidemia (MMA) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Methylmalonic Acidemia (MMA) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Methylmalonic Acidemia (MMA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Methylmalonic Acidemia (MMA) Market Growth Rate Analysis
- 5.4. Global Methylmalonic Acidemia (MMA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Methylmalonic Acidemia (MMA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Methylmalonic Acidemia (MMA) Total Addressable Market (TAM)
6. Methylmalonic Acidemia (MMA) Market Segmentation
- 6.1. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Acidosis
- Ketosis
- Hyperammonemia
- Hypoglycaemia
- Hyperglycaemia
- Neutropenia
- Other Indications
- 6.2. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Homocystinuria
- Isolated Methylmalonic Acidurias
- Combined methylmalonic Aciduria
- 6.3. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Pharmacies
- Clinics
- Other Distribution Channels
- 6.4. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Acidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Metabolic Acidosis
- Lactic Acidosis
- 6.5. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Ketosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Starvation-Induced Ketosis
- Diabetic Ketoacidosis
- 6.6. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Hyperammonemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Acute Hyperammonemia
- Chronic Hyperammonemia
- 6.7. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Hypoglycemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Fasting Hypoglycemia
- Reactive Hypoglycemi
- 6.8. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Neutropenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Severe Neutropenia
- Cyclic Neutropenia
- 6.9. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Failure to Thrive
- Developmental Delays
- Neurological Symptoms
- Renal Dysfunction
7. Methylmalonic Acidemia (MMA) Market Regional And Country Analysis
- 7.1. Global Methylmalonic Acidemia (MMA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Methylmalonic Acidemia (MMA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Methylmalonic Acidemia (MMA) Market
- 8.1. Asia-Pacific Methylmalonic Acidemia (MMA) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Methylmalonic Acidemia (MMA) Market
- 9.1. China Methylmalonic Acidemia (MMA) Market Overview
- 9.2. China Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Methylmalonic Acidemia (MMA) Market
- 10.1. India Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Methylmalonic Acidemia (MMA) Market
- 11.1. Japan Methylmalonic Acidemia (MMA) Market Overview
- 11.2. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Methylmalonic Acidemia (MMA) Market
- 12.1. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Methylmalonic Acidemia (MMA) Market
- 13.1. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Methylmalonic Acidemia (MMA) Market
- 14.1. South Korea Methylmalonic Acidemia (MMA) Market Overview
- 14.2. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Methylmalonic Acidemia (MMA) Market
- 15.1. Western Europe Methylmalonic Acidemia (MMA) Market Overview
- 15.2. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Methylmalonic Acidemia (MMA) Market
- 16.1. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Methylmalonic Acidemia (MMA) Market
- 17.1. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Methylmalonic Acidemia (MMA) Market
- 18.1. France Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Methylmalonic Acidemia (MMA) Market
- 19.1. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Methylmalonic Acidemia (MMA) Market
- 20.1. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Methylmalonic Acidemia (MMA) Market
- 21.1. Eastern Europe Methylmalonic Acidemia (MMA) Market Overview
- 21.2. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Methylmalonic Acidemia (MMA) Market
- 22.1. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Methylmalonic Acidemia (MMA) Market
- 23.1. North America Methylmalonic Acidemia (MMA) Market Overview
- 23.2. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Methylmalonic Acidemia (MMA) Market
- 24.1. USA Methylmalonic Acidemia (MMA) Market Overview
- 24.2. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Methylmalonic Acidemia (MMA) Market
- 25.1. Canada Methylmalonic Acidemia (MMA) Market Overview
- 25.2. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Methylmalonic Acidemia (MMA) Market
- 26.1. South America Methylmalonic Acidemia (MMA) Market Overview
- 26.2. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Methylmalonic Acidemia (MMA) Market
- 27.1. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Methylmalonic Acidemia (MMA) Market
- 28.1. Middle East Methylmalonic Acidemia (MMA) Market Overview
- 28.2. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Methylmalonic Acidemia (MMA) Market
- 29.1. Africa Methylmalonic Acidemia (MMA) Market Overview
- 29.2. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Methylmalonic Acidemia (MMA) Market Competitive Landscape And Company Profiles
- 30.1. Methylmalonic Acidemia (MMA) Market Competitive Landscape
- 30.2. Methylmalonic Acidemia (MMA) Market Company Profiles
- 30.2.1. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Lonza Group Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Alexion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Ironwood Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Methylmalonic Acidemia (MMA) Market Other Major And Innovative Companies
- 31.1. Wockhardt Limited
- 31.2. Spectrum Chemical Manufacturing Corp.
- 31.3. Asklepios BioPharmaceutical Inc. (AskBio)
- 31.4. Selecta Biosciences Inc.
- 31.5. BTG International Inc.
- 31.6. BridgeBio Pharma Inc.
- 31.7. VectivBio Holding AG
- 31.8. Supriya Lifescience Ltd.
- 31.9. Recordati Rare Diseases Inc.
- 31.10. Agios Pharmaceuticals Inc.
- 31.11. AdvaCare Pharma USA LLC
- 31.12. LogicBio Therapeutics Inc.
- 31.13. HemoShear Therapeutics LLC
- 31.14. Manus Aktteva Biopharma LLP
- 31.15. Deccan Nutraceuticals Pvt. Ltd.
32. Global Methylmalonic Acidemia (MMA) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Methylmalonic Acidemia (MMA) Market
34. Recent Developments In The Methylmalonic Acidemia (MMA) Market
35. Methylmalonic Acidemia (MMA) Market High Potential Countries, Segments and Strategies
- 35.1 Methylmalonic Acidemia (MMA) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Methylmalonic Acidemia (MMA) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Methylmalonic Acidemia (MMA) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
